The case for & against
Bull & Bear analysis
Bearish
OmniAb, Inc. (NASDAQ: OABI) operates in the biopharmaceutical sector, developing and commercializing novel antibody discovery technologies leveraging its unique transgenic chicken platform. The company is positioned as a key player in the evolution of biotech by enabling efficient and scalable antibody generation. With notable partnerships and a diversified pipeline, OmniAb stands to benefit from emerging market opportunities while addressing significant challenges inherent to the industry.
Bull says
- ↑Q2 2026 revenue $13.4M, up 243% YoY driven by milestone payments
- ↑Raised full-year 2026 revenue guidance to $32–36M, signaling confidence
- ↑Partnerships with eight of the top ten pharma firms validate its platform
- ↑Cash reserves of $52M bolster R&D amid high operating expenditures
- ↑Launched OmniUltra and OmniDAB technologies to unlock new market opportunities
- ↑Undervalued by assets (strong book-to-price) and pays a 0.5% dividend
Bear says
- ↓Negative earnings yield (-3.1%) and poor profitability hinder returns
- ↓2026 operating expenses guided at $84–88M imply ~$15M cash burn
- ↓Revenue relies on uneven milestone payments, risking uneven quarters
- ↓P/S ratio 11.2 and 15.8% overvaluation per GF Value suggest correction risk
- ↓Low institutional ownership heightens selling pressure
- ↓Elevated leverage risk and weak profitability metrics threaten stability
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 05-09-2025neutral
Transcript signals
Bull points
- With consecutive quarters showing growth across some key business metrics, I'm proud of OmniAb's progress over the last 18 months, which put us on track for a successful quarter and positions our business and our pipeline very well for a strong year here in 2024.
- We ended Q1 2024 with 80 active partners. 3 new platform license agreements were signed during the quarter, including new agreements with a very well-funded Boston-based venture-backed start-up with ImmunoBiochem Corporation and with the University of Georgia.
- We saw some really nice active program progression in the quarter as 3 programs successfully transitioned from discovery to pre-clinical stage. And at the end of Q1, we had a record 18 programs in pre-clinical and that's the most that we've ever had at that stage.
Bear points
- We experienced a slightly higher level of program attrition in Q1 as compared to recent quarters, all of which was in the discovery stage, with one exception that I'll discuss in a moment.
- we saw the discontinuation of one program at Roche and that is reflected here on this slide. Roche discontinued a Phase 1 program as part of what they've termed a broader internal portfolio shaping initiative there, that they've discussed publicly in some level of detail.
- Total revenue for the first quarter was $3.8 million compared to $16.9 million in the prior year quarter. The decrease was primarily due to the recognition of the TECVAYLI EU launch milestone of $10 million that was recorded in the first quarter of 2023.
Read full transcript analysis ›